Sickle Cell Disease Treatment Market By Drug Type (Hydroxyurea, Oxybryta, Adakveo, Others), By Type (Sickle Cell Anemia, HbSC, Others), By Route of Administration (Oral, Parenteral): Global Opportunity Analysis and Industry Forecast, 2021-2031

Sickle Cell Disease Treatment Market

When a person inherits two abnormal copies of the β-globin gene (HBB), one from each parent, which produces hemoglobin “S”. This hemoglobin “S” is an abnormal form of hemoglobin causing red cells to become rigid and sickle shape. The most common type of sickle cell disease is known as sickle cell anemia. It results in an abnormality in the oxygen-carrying protein hemoglobin found in red blood cells.

The sickle cell disease treatment market growth driven by increase in prevalence of sickle cell disease, rise in pipeline products, and surge in demand for sickle cell disease drugs. In addition, expansion of R&D pipeline, ongoing medicine approvals, and strong growth potential in unexplored new markets are expected to provide numerous sickle cell disease treatment market opportunity for the market growth during the forecast period. For instance, in November 2019, FDA approved Oxbryta (voxeletor), to treat the sickle cell disease, which is expected to boost the market growth.

Moreover, increase in initiatives taken by government of various countries for promoting access programmes and expanding distribution network for sickle cell disease drugs are some sickle cell disease treatment market trends contribute toward the growth of the market. For instance, Emmaus announced the agreement with Mc Kesson Plasma and Biologics LLC. to expand the distribution network of Endari for sickle cell disease patients.

The outbreak of COVID-19 has resulted in a significant decline in demand for sickle cell disease treatments across several sectors, particularly the health and pharmaceutical sector. Factors such as decline in hospitalizations, ER visits, duration of stay, and decrease in people who receive routine follow-up care from a hematologist restraint the sickle cell disease treatment industry during COVID-19.

The sickle cell disease treatment market size is segmented on the basis of drug type, type, route of administration, and region. By drug type, the market is segmented into hydroxyurea, oxbryta, adakveo and others. The others segment further includes, Endari, pain-relieving medication, and others. The hydroxyurea segment exhibited highest growth in 2021, owing to high adoption of hydroxyurea due to rise in prevalence of sickle cell disease.

On the basis of type, the market is segmented into sickle cell anemia or HbSS, HbSC, and others. The others segment further includes, HbS beta thalassemia, HbSD, HbSE, and HbSO. The sickle cell anemia segment exhibited highest sickle cell disease treatment market share in 2021, and is expected to remain dominant during the forecast period, owing to increase in prevalence of sickle cell anemia. For instance, according to National Library of Medicine (NIH), the annual number of newborns with sickle cell anemia is estimated to exceed 400,000 by 2050.

On the basis of route of administration, the market is segmented into oral and parenteral. The oral segment dominated the market in 2021. This was attributed to advantages associated with oral route, such as more pre-determined doses, convenient to administer drug, and patient self-administration. In addition, oral route is most preferred due to its cost effectiveness and strong patient compliance, which further fuels the segment growth.

North America accounted for the largest sickle cell disease treatment market share of the global sickle cell disease market in 2021, owing to factors such as availability of treatments for sickle cell disease, well-established regulations for approval and distribution of products & services. 

However, Asia-Pacific is expected to fastest CAGR during the sickle cell disease treatment market analysis, owing to increase in cases of sickle cell disease. Moreover, growth in investments for development of advanced treatment for sickle cell disease is the key driving factor that boosts the growth of the market in the region.

KEY FINDINGS OF THE STUDY 

 

• Based on drug type, the hydroxyurea segment held largest share in the global sickle cell disease treatment industry in 2021.

• On the basis of type, the sickle cell anemia segment held largest market share in 2021, and is expected to continue this trend during the forecast period.

• Based on route of administration, oral segment dominated the market in 2021. However, parenteral segment is expected to grow at a CAGR of 4.3% during the forecast period.

• On the basis of region, North America held largest share in the global market in 2021. However, Asia-Pacific is anticipated to grow at the highest CAGR of 5.7% during the forecast period.

Overview

The global sickle cell disease treatment market was valued at $ 1,078.88 million in 2021 and is projected to reach $1,618.78million by 2031, registering a CAGR of 4.1% from 2022 to 2031. 

The round and healthy red blood cells move through small blood channels to deliver oxygen to every part of the body. In sickle cell disease patients, the hemoglobin is abnormal, which causes the red blood cells get transformed into C-shaped cells called as a sickles and become hard and sticky. The symptoms of sickle cell disease includes, anemia, episodes of pain, and swelling of hands and feet. 

The growth of the global sickle cell disease treatment market is majorly driven by increase in prevalence of sickle cell disease, availability of sickle cell disease medications, and initiatives taken by government to develop better healthcare infrastructure. For instance, according to Centers for Disease Control and Prevention, sickle cell disease affects 1 of every 360 African new born and 1 in 13 babies born carries the sickle cell trait. 

However, high cost of treatment associated with sickle cell disease treatment and side effects associated with sickle cell disease may hinder the market growth. Conversely, expansion of R&D pipeline, ongoing medicine approvals, and strong growth potential in unexplored new markets are expected to provide numerous opportunities for the market growth during the forecast period.

The global sickle cell disease treatment market is segmented on the basis of drug type, type, route of administration, and region to provide a detailed assessment of the market. By drug type, it is segmented into hydroxyurea, oxbryta, adakveo, and others. The others segment further includes, endari, pain-relieving medication, and others. 

In addition, on the basis of type is segmented into sickle cell anemia or HbSS, HbSC, and others. The others segment further includes, HbS beta thalassemia, HbSD, HbSE, and HbSO. By route of administration, it is segmented into oral and parenteral. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. The key market players profiled in the report include Agios Pharmaceuticals, Bristol Myers Squibb Company, CRISPR Therapeutics, Editas Medicine, Emmaus Life Sciences, Inc., Global Blood Therapeutics, Inc., Medunic USA, Inc., Novartis AG, Novo Nordisk, and Vifor Pharma.

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the sickle cell disease treatment market analysis from 2021 to 2031 to identify the prevailing sickle cell disease treatment market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the sickle cell disease treatment market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global sickle cell disease treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

○ Vifor Pharm

Scope of Sickle Cell Disease Treatment Market Report

1.1.Report description

1.2.Key market segments

1.3.Key benefits to the stakeholders

1.4.Research Methodology

1.4.1.Secondary research

1.4.2.Primary research

1.4.3.Analyst tools and models

2.1.Key findings of the study

2.2.CXO Perspective

3.1.Market definition and scope

3.2.Key findings

3.2.1.Top investment pockets

3.3.Porter’s five forces analysis

3.4.Top player positioning

3.5.Market dynamics

3.5.1.Drivers

3.5.2.Restraints

3.5.3.Opportunities

3.6.COVID-19 Impact Analysis on the market

3.7.Patent Landscape

4.1 Overview

4.1.1 Market size and forecast

4.2 Hydroxyurea

4.2.1 Key market trends, growth factors and opportunities

4.2.2 Market size and forecast, by region

4.2.3 Market analysis by country

4.2.4 Hydroxyurea Sickle Cell Disease Treatment Market by Distribution Channel

4.2.4.1 Hospitals Pharmacies Market size and forecast, by region

4.2.4.2 Drug Stores and Retail Pharmacies Market size and forecast, by region

4.2.4.3 Online Providers Market size and forecast, by region

4.3 Oxybryta

4.3.1 Key market trends, growth factors and opportunities

4.3.2 Market size and forecast, by region

4.3.3 Market analysis by country

4.4 Adakveo

4.4.1 Key market trends, growth factors and opportunities

4.4.2 Market size and forecast, by region

4.4.3 Market analysis by country

4.5 Others

4.5.1 Key market trends, growth factors and opportunities

4.5.2 Market size and forecast, by region

4.5.3 Market analysis by country

5.1 Overview

5.1.1 Market size and forecast

5.2 Sickle Cell Anemia

5.2.1 Key market trends, growth factors and opportunities

5.2.2 Market size and forecast, by region

5.2.3 Market analysis by country

5.3 HbSC

5.3.1 Key market trends, growth factors and opportunities

5.3.2 Market size and forecast, by region

5.3.3 Market analysis by country

5.4 Others

5.4.1 Key market trends, growth factors and opportunities

5.4.2 Market size and forecast, by region

5.4.3 Market analysis by country

6.1 Overview

6.1.1 Market size and forecast

6.2 Oral

6.2.1 Key market trends, growth factors and opportunities

6.2.2 Market size and forecast, by region

6.2.3 Market analysis by country

6.3 Parenteral

6.3.1 Key market trends, growth factors and opportunities

6.3.2 Market size and forecast, by region

6.3.3 Market analysis by country

7.1 Overview

7.1.1 Market size and forecast

7.2 North America

7.2.1 Key trends and opportunities

7.2.2 North America Market size and forecast, by Drug Type

7.2.2.1 North America Hydroxyurea Sickle Cell Disease Treatment Market by Distribution Channel

7.2.3 North America Market size and forecast, by Type

7.2.4 North America Market size and forecast, by Route of Administration

7.2.5 North America Market size and forecast, by country

7.2.5.1 U.S.

7.2.5.1.1 Market size and forecast, by Drug Type

7.2.5.1.2 Market size and forecast, by Type

7.2.5.1.3 Market size and forecast, by Route of Administration

7.2.5.2 Canada

7.2.5.2.1 Market size and forecast, by Drug Type

7.2.5.2.2 Market size and forecast, by Type

7.2.5.2.3 Market size and forecast, by Route of Administration

7.2.5.3 Mexico

7.2.5.3.1 Market size and forecast, by Drug Type

7.2.5.3.2 Market size and forecast, by Type

7.2.5.3.3 Market size and forecast, by Route of Administration

7.3 Europe

7.3.1 Key trends and opportunities

7.3.2 Europe Market size and forecast, by Drug Type

7.3.2.1 Europe Hydroxyurea Sickle Cell Disease Treatment Market by Distribution Channel

7.3.3 Europe Market size and forecast, by Type

7.3.4 Europe Market size and forecast, by Route of Administration

7.3.5 Europe Market size and forecast, by country

7.3.5.1 Germany

7.3.5.1.1 Market size and forecast, by Drug Type

7.3.5.1.2 Market size and forecast, by Type

7.3.5.1.3 Market size and forecast, by Route of Administration

7.3.5.2 France

7.3.5.2.1 Market size and forecast, by Drug Type

7.3.5.2.2 Market size and forecast, by Type

7.3.5.2.3 Market size and forecast, by Route of Administration

7.3.5.3 UK

7.3.5.3.1 Market size and forecast, by Drug Type

7.3.5.3.2 Market size and forecast, by Type

7.3.5.3.3 Market size and forecast, by Route of Administration

7.3.5.4 Italy

7.3.5.4.1 Market size and forecast, by Drug Type

7.3.5.4.2 Market size and forecast, by Type

7.3.5.4.3 Market size and forecast, by Route of Administration

7.3.5.5 Spain

7.3.5.5.1 Market size and forecast, by Drug Type

7.3.5.5.2 Market size and forecast, by Type

7.3.5.5.3 Market size and forecast, by Route of Administration

7.3.5.6 Rest of Europe

7.3.5.6.1 Market size and forecast, by Drug Type

7.3.5.6.2 Market size and forecast, by Type

7.3.5.6.3 Market size and forecast, by Route of Administration

7.4 Asia-Pacific

7.4.1 Key trends and opportunities

7.4.2 Asia-Pacific Market size and forecast, by Drug Type

7.4.2.1 Asia-Pacific Hydroxyurea Sickle Cell Disease Treatment Market by Distribution Channel

7.4.3 Asia-Pacific Market size and forecast, by Type

7.4.4 Asia-Pacific Market size and forecast, by Route of Administration

7.4.5 Asia-Pacific Market size and forecast, by country

7.4.5.1 Japan

7.4.5.1.1 Market size and forecast, by Drug Type

7.4.5.1.2 Market size and forecast, by Type

7.4.5.1.3 Market size and forecast, by Route of Administration

7.4.5.2 China

7.4.5.2.1 Market size and forecast, by Drug Type

7.4.5.2.2 Market size and forecast, by Type

7.4.5.2.3 Market size and forecast, by Route of Administration

7.4.5.3 India

7.4.5.3.1 Market size and forecast, by Drug Type

7.4.5.3.2 Market size and forecast, by Type

7.4.5.3.3 Market size and forecast, by Route of Administration

7.4.5.4 Australia

7.4.5.4.1 Market size and forecast, by Drug Type

7.4.5.4.2 Market size and forecast, by Type

7.4.5.4.3 Market size and forecast, by Route of Administration

7.4.5.5 South Korea

7.4.5.5.1 Market size and forecast, by Drug Type

7.4.5.5.2 Market size and forecast, by Type

7.4.5.5.3 Market size and forecast, by Route of Administration

7.4.5.6 Rest of Asia-Pacific

7.4.5.6.1 Market size and forecast, by Drug Type

7.4.5.6.2 Market size and forecast, by Type

7.4.5.6.3 Market size and forecast, by Route of Administration

7.5 LAMEA

7.5.1 Key trends and opportunities

7.5.2 LAMEA Market size and forecast, by Drug Type

7.5.2.1 LAMEA Hydroxyurea Sickle Cell Disease Treatment Market by Distribution Channel

7.5.3 LAMEA Market size and forecast, by Type

7.5.4 LAMEA Market size and forecast, by Route of Administration

7.5.5 LAMEA Market size and forecast, by country

7.5.5.1 Brazil

7.5.5.1.1 Market size and forecast, by Drug Type

7.5.5.1.2 Market size and forecast, by Type

7.5.5.1.3 Market size and forecast, by Route of Administration

7.5.5.2 Saudi Arabia

7.5.5.2.1 Market size and forecast, by Drug Type

7.5.5.2.2 Market size and forecast, by Type

7.5.5.2.3 Market size and forecast, by Route of Administration

7.5.5.3 South Africa

7.5.5.3.1 Market size and forecast, by Drug Type

7.5.5.3.2 Market size and forecast, by Type

7.5.5.3.3 Market size and forecast, by Route of Administration

7.5.5.4 Rest of LAMEA

7.5.5.4.1 Market size and forecast, by Drug Type

7.5.5.4.2 Market size and forecast, by Type

7.5.5.4.3 Market size and forecast, by Route of Administration

8.1. Introduction

8.2. Top winning strategies

8.3. Product Mapping of Top 10 Player

8.4. Competitive Dashboard

8.5. Competitive Heatmap

8.6. Key developments

9.1 Agios Pharmaceuticals

9.1.1 Company overview

9.1.2 Company snapshot

9.1.3 Operating business segments

9.1.4 Product portfolio

9.1.5 Business performance

9.1.6 Key strategic moves and developments

9.2 Bristol-Myers Squibb

9.2.1 Company overview

9.2.2 Company snapshot

9.2.3 Operating business segments

9.2.4 Product portfolio

9.2.5 Business performance

9.2.6 Key strategic moves and developments

9.3 CRISPR Therapeutics

9.3.1 Company overview

9.3.2 Company snapshot

9.3.3 Operating business segments

9.3.4 Product portfolio

9.3.5 Business performance

9.3.6 Key strategic moves and developments

9.4 editas Medicine

9.4.1 Company overview

9.4.2 Company snapshot

9.4.3 Operating business segments

9.4.4 Product portfolio

9.4.5 Business performance

9.4.6 Key strategic moves and developments

9.5 Emmaus Life Sciences, Inc.

9.5.1 Company overview

9.5.2 Company snapshot

9.5.3 Operating business segments

9.5.4 Product portfolio

9.5.5 Business performance

9.5.6 Key strategic moves and developments

9.6 Global Blood Therapeutics, Inc.

9.6.1 Company overview

9.6.2 Company snapshot

9.6.3 Operating business segments

9.6.4 Product portfolio

9.6.5 Business performance

9.6.6 Key strategic moves and developments

9.7 Medunic USA Inc.

9.7.1 Company overview

9.7.2 Company snapshot

9.7.3 Operating business segments

9.7.4 Product portfolio

9.7.5 Business performance

9.7.6 Key strategic moves and developments

9.8 Novartis AG

9.8.1 Company overview

9.8.2 Company snapshot

9.8.3 Operating business segments

9.8.4 Product portfolio

9.8.5 Business performance

9.8.6 Key strategic moves and developments

9.9 Novo Nordisk

9.9.1 Company overview

9.9.2 Company snapshot

9.9.3 Operating business segments

9.9.4 Product portfolio

9.9.5 Business performance

9.9.6 Key strategic moves and developments

9.10 Vifor Pharma

9.10.1 Company overview

9.10.2 Company snapshot

9.10.3 Operating business segments

9.10.4 Product portfolio

9.10.5 Business performance

9.10.6 Key strategic moves and development

LIST OF TABLES

TABLE 1. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 2. SICKLE CELL DISEASE TREATMENT MARKET, FOR HYDROXYUREA, BY REGION, 2021-2031 ($MILLION)

TABLE 3. SICKLE CELL DISEASE TREATMENT MARKET FOR HYDROXYUREA, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 4. GLOBAL HYDROXYUREA SICKLE CELL DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 5. SICKLE CELL DISEASE TREATMENT MARKET, FOR HOSPITALS PHARMACIES, BY REGION, 2021-2031 ($MILLION)

TABLE 6. SICKLE CELL DISEASE TREATMENT MARKET, FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)

TABLE 7. SICKLE CELL DISEASE TREATMENT MARKET, FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)

TABLE 8. SICKLE CELL DISEASE TREATMENT MARKET, FOR OXYBRYTA, BY REGION, 2021-2031 ($MILLION)

TABLE 9. SICKLE CELL DISEASE TREATMENT MARKET FOR OXYBRYTA, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 10. SICKLE CELL DISEASE TREATMENT MARKET, FOR ADAKVEO, BY REGION, 2021-2031 ($MILLION)

TABLE 11. SICKLE CELL DISEASE TREATMENT MARKET FOR ADAKVEO, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 12. SICKLE CELL DISEASE TREATMENT MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)

TABLE 13. SICKLE CELL DISEASE TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 14. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 15. SICKLE CELL DISEASE TREATMENT MARKET, FOR SICKLE CELL ANEMIA, BY REGION, 2021-2031 ($MILLION)

TABLE 16. SICKLE CELL DISEASE TREATMENT MARKET FOR SICKLE CELL ANEMIA, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 17. SICKLE CELL DISEASE TREATMENT MARKET, FOR HBSC, BY REGION, 2021-2031 ($MILLION)

TABLE 18. SICKLE CELL DISEASE TREATMENT MARKET FOR HBSC, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 19. SICKLE CELL DISEASE TREATMENT MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)

TABLE 20. SICKLE CELL DISEASE TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 21. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 22. SICKLE CELL DISEASE TREATMENT MARKET, FOR ORAL, BY REGION, 2021-2031 ($MILLION)

TABLE 23. SICKLE CELL DISEASE TREATMENT MARKET FOR ORAL, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 24. SICKLE CELL DISEASE TREATMENT MARKET, FOR PARENTERAL, BY REGION, 2021-2031 ($MILLION)

TABLE 25. SICKLE CELL DISEASE TREATMENT MARKET FOR PARENTERAL, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 26. SICKLE CELL DISEASE TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)

TABLE 27. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 28. NORTH AMERICA HYDROXYUREA SICKLE CELL DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 29. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 30. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 31. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 32. U.S. SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 33. U.S. SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 34. U.S. SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 35. CANADA SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 36. CANADA SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 37. CANADA SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 38. MEXICO SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 39. MEXICO SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 40. MEXICO SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 41. EUROPE SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 42. EUROPE HYDROXYUREA SICKLE CELL DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 43. EUROPE SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 44. EUROPE SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 45. EUROPE SICKLE CELL DISEASE TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 46. GERMANY SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 47. GERMANY SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 48. GERMANY SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 49. FRANCE SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 50. FRANCE SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 51. FRANCE SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 52. UK SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 53. UK SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 54. UK SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 55. ITALY SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 56. ITALY SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 57. ITALY SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 58. SPAIN SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 59. SPAIN SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 60. SPAIN SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 61. REST OF EUROPE SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 62. REST OF EUROPE SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 63. REST OF EUROPE SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 64. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 65. ASIA-PACIFIC HYDROXYUREA SICKLE CELL DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 66. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 67. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 68. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 69. JAPAN SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 70. JAPAN SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 71. JAPAN SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 72. CHINA SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 73. CHINA SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 74. CHINA SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 75. INDIA SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 76. INDIA SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 77. INDIA SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 78. AUSTRALIA SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 79. AUSTRALIA SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 80. AUSTRALIA SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 81. SOUTH KOREA SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 82. SOUTH KOREA SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 83. SOUTH KOREA SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 84. REST OF ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 85. REST OF ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 86. REST OF ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 87. LAMEA SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 88. LAMEA HYDROXYUREA SICKLE CELL DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 89. LAMEA SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 90. LAMEA SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 91. LAMEA SICKLE CELL DISEASE TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 92. BRAZIL SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 93. BRAZIL SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 94. BRAZIL SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 95. SAUDI ARABIA SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 96. SAUDI ARABIA SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 97. SAUDI ARABIA SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 98. SOUTH AFRICA SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 99. SOUTH AFRICA SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 100. SOUTH AFRICA SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 101. REST OF LAMEA SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)

TABLE 102. REST OF LAMEA SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 103. REST OF LAMEA SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)

TABLE 104.AGIOS PHARMACEUTICALS: COMPANY SNAPSHOT

TABLE 105.AGIOS PHARMACEUTICALS: OPERATING SEGMENTS

TABLE 106.AGIOS PHARMACEUTICALS: PRODUCT PORTFOLIO

TABLE 107.AGIOS PHARMACEUTICALS: NET SALES,

TABLE 108.AGIOS PHARMACEUTICALS: KEY STRATERGIES

TABLE 109.BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT

TABLE 110.BRISTOL-MYERS SQUIBB: OPERATING SEGMENTS

TABLE 111.BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO

TABLE 112.BRISTOL-MYERS SQUIBB: NET SALES,

TABLE 113.BRISTOL-MYERS SQUIBB: KEY STRATERGIES

TABLE 114.CRISPR THERAPEUTICS: COMPANY SNAPSHOT

TABLE 115.CRISPR THERAPEUTICS: OPERATING SEGMENTS

TABLE 116.CRISPR THERAPEUTICS: PRODUCT PORTFOLIO

TABLE 117.CRISPR THERAPEUTICS: NET SALES,

TABLE 118.CRISPR THERAPEUTICS: KEY STRATERGIES

TABLE 119.EDITAS MEDICINE: COMPANY SNAPSHOT

TABLE 120.EDITAS MEDICINE: OPERATING SEGMENTS

TABLE 121.EDITAS MEDICINE: PRODUCT PORTFOLIO

TABLE 122.EDITAS MEDICINE: NET SALES,

TABLE 123.EDITAS MEDICINE: KEY STRATERGIES

TABLE 124.EMMAUS LIFE SCIENCES, INC.: COMPANY SNAPSHOT

TABLE 125.EMMAUS LIFE SCIENCES, INC.: OPERATING SEGMENTS

TABLE 126.EMMAUS LIFE SCIENCES, INC.: PRODUCT PORTFOLIO

TABLE 127.EMMAUS LIFE SCIENCES, INC.: NET SALES,

TABLE 128.EMMAUS LIFE SCIENCES, INC.: KEY STRATERGIES

TABLE 129.GLOBAL BLOOD THERAPEUTICS, INC.: COMPANY SNAPSHOT

TABLE 130.GLOBAL BLOOD THERAPEUTICS, INC.: OPERATING SEGMENTS

TABLE 131.GLOBAL BLOOD THERAPEUTICS, INC.: PRODUCT PORTFOLIO

TABLE 132.GLOBAL BLOOD THERAPEUTICS, INC.: NET SALES,

TABLE 133.GLOBAL BLOOD THERAPEUTICS, INC.: KEY STRATERGIES

TABLE 134.MEDUNIC USA INC.: COMPANY SNAPSHOT

TABLE 135.MEDUNIC USA INC.: OPERATING SEGMENTS

TABLE 136.MEDUNIC USA INC.: PRODUCT PORTFOLIO

TABLE 137.MEDUNIC USA INC.: NET SALES,

TABLE 138.MEDUNIC USA INC.: KEY STRATERGIES

TABLE 139.NOVARTIS AG: COMPANY SNAPSHOT

TABLE 140.NOVARTIS AG: OPERATING SEGMENTS

TABLE 141.NOVARTIS AG: PRODUCT PORTFOLIO

TABLE 142.NOVARTIS AG: NET SALES,

TABLE 143.NOVARTIS AG: KEY STRATERGIES

TABLE 144.NOVO NORDISK: COMPANY SNAPSHOT

TABLE 145.NOVO NORDISK: OPERATING SEGMENTS

TABLE 146.NOVO NORDISK: PRODUCT PORTFOLIO

TABLE 147.NOVO NORDISK: NET SALES,

TABLE 148.NOVO NORDISK: KEY STRATERGIES

TABLE 149.VIFOR PHARMA: COMPANY SNAPSHOT

TABLE 150.VIFOR PHARMA: OPERATING SEGMENTS

TABLE 151.VIFOR PHARMA: PRODUCT PORTFOLIO

TABLE 152.VIFOR PHARMA: NET SALES,

TABLE 153.VIFOR PHARMA: KEY STRATERGIES LIST OF FIGURES

FIGURE 1.SICKLE CELL DISEASE TREATMENT MARKET SEGMENTATION

FIGURE 2.SICKLE CELL DISEASE TREATMENT MARKET,2021-2031

FIGURE 3.SICKLE CELL DISEASE TREATMENT MARKET,2021-2031

FIGURE 4. TOP INVESTMENT POCKETS, BY REGION

FIGURE 5.PORTER FIVE-1

FIGURE 6.PORTER FIVE-2

FIGURE 7.PORTER FIVE-3

FIGURE 8.PORTER FIVE-4

FIGURE 9.PORTER FIVE-5

FIGURE 10.TOP PLAYER POSITIONING

FIGURE 11.SICKLE CELL DISEASE TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 12.PATENT ANALYSIS BY COMPANY

FIGURE 13.PATENT ANALYSIS BY COUNTRY

FIGURE 14.SICKLE CELL DISEASE TREATMENT MARKET,BY DRUG TYPE,2021(%)

FIGURE 15.COMPARATIVE SHARE ANALYSIS OF HYDROXYUREA SICKLE CELL DISEASE TREATMENT MARKET,2021-2031(%)

FIGURE 16.COMPARATIVE SHARE ANALYSIS OF OXYBRYTA SICKLE CELL DISEASE TREATMENT MARKET,2021-2031(%)

FIGURE 17.COMPARATIVE SHARE ANALYSIS OF ADAKVEO SICKLE CELL DISEASE TREATMENT MARKET,2021-2031(%)

FIGURE 18.COMPARATIVE SHARE ANALYSIS OF OTHERS SICKLE CELL DISEASE TREATMENT MARKET,2021-2031(%)

FIGURE 19.SICKLE CELL DISEASE TREATMENT MARKET,BY TYPE,2021(%)

FIGURE 20.COMPARATIVE SHARE ANALYSIS OF SICKLE CELL ANEMIA SICKLE CELL DISEASE TREATMENT MARKET,2021-2031(%)

FIGURE 21.COMPARATIVE SHARE ANALYSIS OF HBSC SICKLE CELL DISEASE TREATMENT MARKET,2021-2031(%)

FIGURE 22.COMPARATIVE SHARE ANALYSIS OF OTHERS SICKLE CELL DISEASE TREATMENT MARKET,2021-2031(%)

FIGURE 23.SICKLE CELL DISEASE TREATMENT MARKET,BY ROUTE OF ADMINISTRATION,2021(%)

FIGURE 24.COMPARATIVE SHARE ANALYSIS OF ORAL SICKLE CELL DISEASE TREATMENT MARKET,2021-2031(%)

FIGURE 25.COMPARATIVE SHARE ANALYSIS OF PARENTERAL SICKLE CELL DISEASE TREATMENT MARKET,2021-2031(%)

FIGURE 26.SICKLE CELL DISEASE TREATMENT MARKET BY REGION,2021

FIGURE 27.U.S. SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)

FIGURE 28.CANADA SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)

FIGURE 29.MEXICO SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)

FIGURE 30.GERMANY SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)

FIGURE 31.FRANCE SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)

FIGURE 32.UK SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)

FIGURE 33.ITALY SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)

FIGURE 34.SPAIN SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)

FIGURE 35.REST OF EUROPE SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)

FIGURE 36.JAPAN SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)

FIGURE 37.CHINA SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)

FIGURE 38.INDIA SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)

FIGURE 39.AUSTRALIA SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)

FIGURE 40.SOUTH KOREA SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)

FIGURE 41.REST OF ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)

FIGURE 42.BRAZIL SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)

FIGURE 43.SAUDI ARABIA SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)

FIGURE 44.SOUTH AFRICA SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)

FIGURE 45.REST OF LAMEA SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)

FIGURE 46. TOP WINNING STRATEGIES, BY YEAR

FIGURE 47. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 48. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 49.PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 50.COMPETITIVE DASHBOARD

FIGURE 51.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS

FIGURE 52.AGIOS PHARMACEUTICALS.: NET SALES ,($MILLION)

FIGURE 53.BRISTOL-MYERS SQUIBB.: NET SALES ,($MILLION)

FIGURE 54.CRISPR THERAPEUTICS.: NET SALES ,($MILLION)

FIGURE 55.EDITAS MEDICINE.: NET SALES ,($MILLION)

FIGURE 56.EMMAUS LIFE SCIENCES, INC..: NET SALES ,($MILLION)

FIGURE 57.GLOBAL BLOOD THERAPEUTICS, INC..: NET SALES ,($MILLION)

FIGURE 58.MEDUNIC USA INC..: NET SALES ,($MILLION)

FIGURE 59.NOVARTIS AG.: NET SALES ,($MILLION)

FIGURE 60.NOVO NORDISK.: NET SALES ,($MILLION)

FIGURE 61.VIFOR PHARMA.: NET SALES ,($MILLION